Can a cholesterol drug calm inflammation in diabetes? new study explores.
NCT ID NCT03829046
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study looked at how evolocumab (Repatha) affects markers of inflammation and blood clotting in 41 people with type 2 diabetes and heart or blood vessel disease. Participants received either evolocumab or a placebo injection every 4 weeks for 3 doses. The goal was to understand short-term changes in these markers, not to treat the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROVASCULAR DYSFUNCTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
St. Michael's - University of Toronto
Toronto, Ontario, M5B1W8, Canada
Conditions
Explore the condition pages connected to this study.